

Table 4. Characteristics of the heart failure cohort stratified by treatment and genotype

	Placebo group (<i>n</i> = 525)				Bucindolol group (<i>n</i> = 515)			
	Arg Hmz (<i>n</i> = 236)	Arg/Gly Het (<i>n</i> = 237)	Gly Hmz (<i>n</i> = 52)	Gly carrier (<i>n</i> = 289)	Arg Hmz (<i>n</i> = 257)	Arg/Gly Het (<i>n</i> = 216)	Gly Hmz (<i>n</i> = 42)	Gly carrier (<i>n</i> = 258)
Age	60 ± 11	60 ± 12	59 ± 13	60 ± 12.5	59 ± 11	61 ± 12	56 ± 14	60 ± 12
Sex <i>n</i> (%)								
Male <i>n</i> (%)	187 (79)	183 (77)	42 (81)	225 (78)	206 (80)	173 (8)	34 (81)	207 (80)
Female <i>n</i> (%)	49 (21)	54 (23)	10 (19)	64 (22)	51 (20)	43 (20)	8 (19)	51 (20)
Race <i>n</i> (%)								
Nonblack	212 (90)	182 (77)	33 (63)	215 (74)	215 (84)	165 (76)	26 (62)	191 (74)
Black	24 (10)	55 (23)	19 (37)	74 (26)	42 (16)	51 (24)	16 (38)	67 (26)
Etiology <i>n</i> (%)								
Ischemic	145 (61)	137 (58)	34 (65)	171 (59)	138 (54)	129 (60)	23 (55)	152 (59)
Nonischemic	91 (39)	100 (42)	18 (35)	118 (41)	119 (46)	87 (40)	19 (45)	106 (41)
NYHA <i>n</i> (%)								
III	223 (94)	217 (92)	48 (92)	265 (92)	242 (94)	194 (90)	36 (86)	230 (89)
IV	13 (6)	20 (8)	4 (8)	24 (8)	15 (6)	22 (10)	6 (14)	28 (11)
LVEF, %	2 ± 7	24 ± 7	23 ± 6	24 ± 7	23 ± 7	23 ± 7	22 ± 6	23 ± 7
LVEF change*	3.9 ± 7	2.0 ± 6	4.1 ± 8	3.1 ± 9	8.0 ± 10	6.2 ± 8	5.7 ± 8	6.9 ± 9
RVEF, %	37 ± 13.6	35 ± 12.9	33 ± 11.1	34 ± 12.6	37 ± 12.7	34 ± 13.7	34 ± 13.5	33.9 ± 13.6
RVEF change*	0.7 ± 12	2.3 ± 12	7.7 ± 15	33 ± 13	4.0 ± 13	7.8 ± 12	4.8 ± 10	7.4 ± 12
Baseline HR, bpm	79 ± 13	81 ± 12	80 ± 12	81 ± 12	82 ± 12	81 ± 12	82 ± 14	82 ± 13
HR change, bpm*	-1.3 ± 14	-1.5 ± 13	-5.5 ± 14	-2.2 ± 13	-8.3 ± 14	-11 ± 13	-8.0 ± 12	-10.1 ± 13
Systolic BP, mmHg	118 ± 18	114 ± 17	121 ± 17	117 ± 17	117 ± 17	119 ± 19	123 ± 15	120 ± 18
Systolic BP change,* mmHg	-0.5 ± 18	0.8 ± 17	4.4 ± 17	1.5 ± 17	-0.6 ± 18	2.6 ± 18	-2.6 ± 17	1.8 ± 18
Mean arterial pressure, mmHg	87 ± 12	86 ± 11	89 ± 10	87 ± 11	87 ± 12	87 ± 12	92 ± 11	88 ± 12
BMI, kg/m ²	27 ± 5	28 ± 6	29 ± 5	28 ± 6	28 ± 5	27 ± 5	29 ± 6	27 ± 5
CHF duration, mos, median)	32	27	39	31	30	32	36	34
Current cigarette smoker, %	17	17	10	16	17	21	12	19
History of diabetes, %	35	32	33	32	37	38	26	36
History of hypertension, %	50	56	65	58	54	61	62	61
Current atrial fibrillation, %	13	11	12	11	9	11	5	10
LBBB, %	25	22	21	22	27	24	21	24
BUN, mg/dl	24 ± 14	23 ± 11	26 ± 18	23 ± 13	23 ± 13	25 ± 14	22 ± 11	24 ± 14
Creatinine, mg/dl	1.2 ± 0.4	1.2 ± 0.4	1.3 ± 0.4	1.2 ± 0.4	1.2 ± 0.4	1.2 ± 0.4	1.2 ± 0.5	1.2 ± 0.4

	Placebo group (n = 525)				Bucindolol group (n = 515)			
	Arg Hmz (n = 236)	Arg/Gly Het (n = 237)	Gly Hmz (n = 52)	Gly carrier (n = 289)	Arg Hmz (n = 257)	Arg/Gly Het (n = 216)	Gly Hmz (n = 42)	Gly carrier (n = 258)
BUN/creatinine	20 ± 7	18 ± 7	19 ± 7	19 ± 17	19 ± 17	20 ± 9	17 ± 4	20 ± 8
BUN/creatinine change [†]	0.6 ± 6.2	0.9 ± 6.7	0.9 ± 4.4	0.9 ± 6.3	0.3 ± 6.0	-0.3 ± 6.2	1.2 ± 3.6	0.0 ± 5.9
PNE (median)	391	425	417	424	423	475	424	426
PNE change [†]	6 ± 268	25 ± 304	52 ± 251	30 ± 294	-67 ± 272	-69 ± 2.65	-79 ± 453	-70 ± 302
Cardiac medications, %								
ACE inhibitor	92	94	85	92	89	92	93	92
Digoxin	89	92	90	91	92	88	86	87
Diuretic	92	93	94	93	93	94	98	95
Hydralazine/isosorbic dinitrate	31	34	25	32	27	32	26	31
Aspirin	43	51	38	48	45	46	33	44
Statin	25	26	40	28	26	30	31	30

Cause of death <i>n</i> (%)	Placebo (<i>n</i> = 525)				Bucindolol (<i>n</i> = 515)			
	Arg Hmz (<i>n</i> = 236)	Het (<i>n</i> = 237)	Gly Hmz (<i>n</i> = 52)	Gly carrier (<i>n</i> = 289)	Arg Hmz (<i>n</i> = 257)	Het (<i>n</i> = 216)	Gly Hmz (<i>n</i> = 42)	Gly carrier (<i>n</i> = 258)
SD w/o preceding HF Sx <i>n</i> (%)	15 (6.4)	15 (6.3)	7 (13.5)	22 (7.6)	13 (5.1)	11 (5.1)	2 (4.8)	13 (5.0)
SD preceded by HF Sx <i>n</i> (%)	5 (2.1)	4 (1.7)	0 (0)	4 (1.45)	3 (1.2)	7 (3.2)	1 (2.4)	8 (3.1)
Pump failure <i>n</i> (%)	13 (5.5)	19 (8.0)	6 (11.5)	25 (8.7)	7 (2.7)	10 (4.6)	1 (2.4)	11 (4.3)
All HF-related (2 + 3) <i>n</i> (%)	18 (7.6)	23 (9.7)	6 (11.5)	29 (10.0)	10 (3.9)	17 (7.9)	2 (4.8)	19 (7.4)
Myocardial infarction <i>n</i> (%)	1 (0.4)	3 (1.3)	0 (0)	3 (1.0)	2 (0.8)	1 (0.5)	0 (0)	1 (0.4)
Cardiac procedure	1	1	0	1	0	0	1	1
Other CV <i>n</i> (%)	5 (2.1)	2 (0.8)	0 (0)	2 (0.7)	1 (0.4)	5 (2.3)	1 (2.4)	6 (2.3)
Non-CV <i>n</i> (%)	4 (1.7)	1 (0.4)	2 (3.8)	3 (1.0)	5 (1.9)	8 (3.7)	1 (2.4)	9 (3.5)
No information <i>n</i> (%)	3 (1.3)	1 (0.4)	0 (0)	1 (0.3)	4 (1.6)	1 (0.5)	0 (0)	1 (0.4)
All deaths <i>n</i> (%)	47 (19.9)	46 (19.4)	15 (28.8)	61 (21.1)	35 (13.6)	43 (19.9)	7 (16.7)	50 (19.4)
No death	189	191	37	228	222	173	35	208

Unless otherwise noted, data are mean \pm SD. BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; Het, heterozygous; Hmz, homozygous; HR, heart rate; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association class; PNE, peripheral norepinephrine; RVEF, right ventricular ejection fraction; HF, heart failure; Sx, symptoms; SD, sudden death; CV, cardiovascular; w/o without.

*Change at 12 months.

†Change at 3 months.